Table 5.

Bleeding and spotting pattern data for women enrolled in a phase 3, multicenter, 13-cycle trial of a drospirenone 4 mg 24/4-day contraceptive regimen

	Bleeding duration, days Median (min, max)	Spotting duration, days Median (min, max)	Prolonged bleeding/spotting > 9 days n/m (%) [95% CI]	Prolonged bleeding/spotting > 14 days n/m (%) [95% CI]	Women with no bleeding/spotting episodes m (%)
Cycles 2–4 N = 609	4.0 (0, 65)	3.0 (0, 34)	132/467 (28.3) [24.2–32.6]	55/467 (11.8) [9.0–15.1]	142 (23.3)
Cycles 5–7 N = 448	3.0 (0, 44)	2.0 (0, 24)	57/317 (18.0) [13.9–22.7]	20/317 (6.3) [3.9–9.6]	131 (29.2)
Cycles 8–10 N = 376	2.0 (0, 48)	1.0 (0, 37)	57/252 (22.6) 17.6–28.3)	18/252 (7.1) [4.3–11.1]	124 (33.0)
Cycles 11–13 N = 310	1.0 (0, 42)	1.0 (0, 31)	32/199 (16.1) [11.3–21.9]	14/199 (7.0) [3.9–1.5]	111 (35.8)

Full-analysis set for combined scheduled and unscheduled bleeding data; N, number of women with data available; n, number of women with prolonged bleeding/spotting in respective cycle; m, number of women with data available in respective cycle; CI, Clopper–Pearson 95% confidence interval.